Travere Therapeutics, Inc.TVTX

Travere Therapeutics, the San Diego biotech that won accelerated FDA approval for FILSPARI (sparsentan) in early June 2026, now faces the unglamorous task of proving that a single drug can pay for a company before the cash runs out. The drug’s label now covers adults and children aged eight and older with FSGS who do not have nephrotic syndrome, expanding the addressable U.S. population to more than 100,000 patients and handing Travere a de facto monopoly on a rare-kidney-condition franchise. The press release calls it “historic,” the kind of word that sounds better in a headline than on a 10-Q that shows a $37.1 million net loss for the quarter ending March 2026.

FILSPARI is Travere’s sole marketed product, a dual endothelin and angiotensin receptor antagonist designed to slash proteinuria in FSGS patients. The science is real, the regulatory win is real, and the market narrative-rare disease, first-in-class, blockbuster potential-is polished to a mirror sheen. Yet the same 10-Q that celebrates the approval also records $127.2 million in quarterly revenue, a figure that sounds substantial until you notice it arrives while the company burns $40.4 million in operating cash and carries just $78.4 million in the bank. The gap between story and spreadsheet is not a rounding error; it is a canyon, and the bridge Travere must cross is commercial execution, not scientific promise.

Travere’s latest quarterly filing (10-Q for the period ending March 31 2026) shows assets of $555.2 million against liabilities of $456.5 million, leaving shareholders with $98.7 million of equity on paper that feels thinner than a dialysis patient’s capillary wall. Cash and equivalents stood at $78.4 million, down from $118.8 million at year-end 2025, a burn rate that would unsettle even the most sanguine biotech treasurer. Inventory crept up by $742,000 to $37.1 million, a figure that might represent growing confidence in FILSPARI’s uptake or merely the cost of carrying a single product without a second act. The company’s diluted loss per share was $0.40, the kind of number that makes buy-and-hold investors reach for the antacid.

The official 10-Q filing for Travere Therapeutics, Inc. (period ending 2026-03-31) is the primary evidence rail for all revenue, income, cash flow and balance-sheet figures cited above. The filing does not contain revenue, profit or cash-flow guidance, and Travere’s recent 8-K and press releases do not supply forward-looking financial metrics.

The company’s commercial challenge is clear: convert regulatory monopoly into real-world prescriptions and revenue before the cash runway shrinks further. Travere’s cash outflow from operating activities in Q1 2026 was negative $40.4 million, and the company’s cash and equivalents balance fell to $78.4 million from $118.8 million at year-end 2025, implying a runway measured in quarters rather than years unless uptake accelerates sharply or additional financing is secured. The filing does not specify whether the company has drawn on credit lines, received milestone payments, or secured debt financing beyond the disclosures already in the 10-Q.

If you want a chart of TVTX, the evidence rail does not supply prices or trading levels, so any chart route would be an external reference rather than a sourced market mechanism. The company’s stock trades on Nasdaq under the ticker TVTX, and the SEC filings index is the definitive source for governance, insider trading and equity issuance activity, but it contains no price data or volume history. For that, you will need to consult your broker’s terminal or an external market-data provider.

What remains unproven is whether FILSPARI’s label expansion will translate into rapid commercial uptake and whether the company can scale reimbursement, distribution and physician adoption fast enough to offset the current burn. Travere’s pipeline beyond FILSPARI is not described in the evidence rail beyond the planned CRO succession, leaving the market to wonder whether the company is a one-drug story with a single regulatory win and a balance sheet that still feels like a start-up’s. The next 12 months will determine whether Travere’s story stays heroic or turns into a cautionary tale of science outpacing finance.